Related Experiment Video
Updated: Jan 14, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
New Kids on the Block: IL-23 Inhibitors in IBD Management
Jacob Jones1, Jeevin Sandhu2, Kara Jones3
1Division of Gastroenterology, Brooke Army Medical Center, 3551 Roger Brooke Drive Ft. Sam, Houston, TX, 78234, USA.
Purpose Of The Review:
Review the efficacy and safety of IL2319 inhibitors in the management of IBD.
Recent Findings:
Risankizumab, mirikizumab, and guselkumab have been found to be efficacious and safe in the management of IBD. IL23p19 inhibitors have been found to be successful in the management of IBD. The new class of biologics adds to the growing armamentarium of medical options and could additionally prove beneficial as dual therapy.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

